Tirzepatide for the Maintenance of Body Weight Reduction: Rationale, Design, and Baseline Characteristics of SURMOUNT‐MAINTAIN
Authors' conclusion
The SURMOUNT-MAINTAIN trial will evaluate whether reducing or continuing the tirzepatide dose as a long-term treatment option may help maintain the reduced BW initially achieved with tirzepatide MTD versus switching to placebo. Combined, this study may provide additional evidence to help tailor patient-centered strategies for maintenance of BW reduction in adults living with obesity.
Study context
- Population
- Adults with obesity (BMI ≥ 30 kg/m² or ≥ 27 kg/m² with ≥ 1 obesity-related comorbidity), excluding T2D
- Comparison
- Once-weekly tirzepatide (5 mg and/or maximum tolerated dose (MTD) of 15 mg or 10 mg) vs placebo for maintenance of body weight (BW) reduction after 60-week open-label tirzepatide MTD weight-loss period
- Primary endpoint
- Percent maintenance of BW reduction achieved during the weight-loss period, among those who reached a BW plateau (< 5% BW change) between Weeks 48 and 60
- Follow-up
- Week 112
Methodological detailsSURMOUNT-MAINTAIN, phase 3b, multicenter, parallel-arm, double-blinded, placebo-controlled, 52-week, in progress
- SURMOUNT-MAINTAIN
- Phase 3b
- Multicenter
- Parallel-arm
- Double-blinded
- Placebo-controlled
- 52-week
- In progress
Primary result
As reported in the abstract
Baseline characteristics
- Female
- 65%
- Age, mean ± SD
- 47 ± 13 years
- BW, mean ± SD
- 114 ± 27 kg
- BMI, mean ± SD
- 40 ± 8 kg/m²
- Waist circumference, mean ± SD
- 119 ± 18 cm
Original publication
Tirzepatide for the Maintenance of Body Weight Reduction: Rationale, Design, and Baseline Characteristics of SURMOUNT‐MAINTAIN. Obesity (Silver Spring). Published 7 September 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →